Simply Wall St.2d agoneutral
Halozyme Therapeutics (HALO) Following Record Results And Higher Guidance Is The Stock Still UndervaluedNotícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
105last 24h
3126last 7d
510● bullish (7d)
311● bearish (7d)
227publishers
GuruFocus.com2d agoneutral
Halozyme Stocks Slip 4.28% Despite 39% Revenue Growth and Modestly Higher GuidanceGuruFocus.com2d agoneutral
Halozyme Therapeutics Inc (HALO) (Q3 2026) Earnings Call Highlights: Record Revenue, Raised ...MT Newswires3d agoneutral
Halozyme Therapeutics Q3 Adjusted Earnings, Revenue Rise; 2026 Guidance LiftedPR Newswire3d agoneutral
HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCEInsider Monkey10d agoneutral
Exelixis (EXEL) vs. BMRN and NBIX: Can CABOMETYX and Pipeline Growth Revive Investor Confidence?Insider Monkey12d agoneutral
Strong Royalties and New Launches Accelerate Halozyme Therapeutics’ (HALO) Growth MomentumBusiness Wire12d agoneutral
Brilliant Labs Launches Halo Glasses, A New Generation of Privacy-First SmartglassesInsider Monkey49d agoneutral
Halozyme Therapeutics (HALO) Proposes $1.05B in Convertibles. Is More Time Worth the Cost?Simply Wall St.53d agoneutral
Is Halozyme Therapeutics (HALO) Fully Priced Ahead Of Its September Conference Run?InvestorsHub67d agoneutral
Halozyme Investor Conferences Put ENHANZE and Expanded Drug Delivery Portfolio in Focus